SEARCH

SEARCH BY CITATION

References

  • 1
    Doran MF, Pond GR, Crowson CS, O'Fallon WM, Gabriel SE. Trends in incidence and mortality in rheumatoid arthritis in Rochester, Minnesota, over a forty-year period. Arthritis Rheum 2002; 46:62531.
  • 2
    Forsblad D'Elia H, Larsen A, Waltbrand E et al. Radiographic joint destruction in postmenopausal rheumatoid arthritis is strongly associated with generalised osteoporosis. Ann Rheum Dis 2003; 62:61723.
  • 3
    Sinigaglia L, Nervetti A, Mela Q et al. A multicenter cross sectional study on bone mineral density in rheumatoid arthritis. Italian Study Group on Bone Mass in Rheumatoid Arthritis. J Rheumatol 2000; 27:25829.
  • 4
    Forsblad D'Elia H, Larsen A, Mattsson LA et al. Influence of hormone replacement therapy on disease progression and bone mineral density in rheumatoid arthritis. J Rheumatol 2003; 30:145663.
  • 5
    Stefanick ML. Estrogens and progestins: background and history, trends in use, and guidelines and regimens approved by the US Food and Drug Administration. Am J Med 2005; 118:6473.
  • 6
    Jochems C, Islander U, Kallkopf A, Lagerquist M, Ohlsson C, Carlsten H. Role of raloxifene as a potent inhibitor of experimental postmenopausal polyarthritis and osteoporosis. Arthritis Rheum 2007; 56:326170.
  • 7
    Jochems C, Lagerquist M, Hakansson C, Ohlsson C, Carlsten H. Long-term anti-arthritic and anti-osteoporotic effects of raloxifene in established experimental postmenopausal polyarthritis. Clin Exp Immunol 2008; 152:5937.
  • 8
    Latham KA, Zamora A, Drought H et al. Estradiol treatment redirects the isotype of the autoantibody response and prevents the development of autoimmune arthritis. J Immunol 2003; 171:58207.
  • 9
    Jochems C, Islander U, Erlandsson M, Verdrengh M, Ohlsson C, Carlsten H. Osteoporosis in experimental postmenopausal polyarthritis: the relative contributions of estrogen deficiency and inflammation. Arthritis Res Ther 2005; 7:R83743.
  • 10
    Nandakumar KS, Holmdahl R. Efficient promotion of collagen antibody induced arthritis (CAIA) using four monoclonal antibodies specific for the major epitopes recognized in both collagen induced arthritis and rheumatoid arthritis. J Immunol Methods 2005; 304:12636.
  • 11
    Burkhardt H, Koller T, Engstrom A et al. Epitope-specific recognition of type II collagen by rheumatoid arthritis antibodies is shared with recognition by antibodies that are arthritogenic in collagen-induced arthritis in the mouse. Arthritis Rheum 2002; 46:233948.
  • 12
    Nandakumar KS, Svensson L, Holmdahl R. Collagen type II-specific monoclonal antibody-induced arthritis in mice: description of the disease and the influence of age, sex, and genes. Am J Pathol 2003; 163:182737.
  • 13
    Lemmen JG, Arends RJ, van Boxtel AL, van der Saag PT, van der Burg B. Tissue- and time-dependent estrogen receptor activation in estrogen reporter mice. J Mol Endocrinol 2004; 32:689701.
  • 14
    van Vollenhoven RF, Houbiers JG, Buttgereit F et al. The selective estrogen receptor alpha agonist Org 37663 induces estrogenic effects but lacks antirheumatic activity: a phase IIa trial investigating efficacy and safety of Org 37663 in postmenopausal female rheumatoid arthritis patients receiving stable background methotrexate or sulfasalazine. Arthritis Rheum 2010; 62:38323.
  • 15
    Roman-Blas JA, Castaneda S, Cutolo M, Herrero-Beaumont G. Efficacy and safety of a selective estrogen receptor-beta agonist, ERB-041, in patients with rheumatoid arthritis. Arthritis Care Res 2010; 62:158893.
  • 16
    Dulos J, Vijn P, van Doorn C et al. Suppression of the inflammatory response in experimental arthritis is mediated via estrogen receptor alpha but not estrogen receptor beta. Arthritis Res Ther 2010; 12:R101.
  • 17
    Harris HA, Albert LM, Leathurby Y et al. Evaluation of an estrogen receptor-beta agonist in animal models of human disease. Endocrinology 2003; 144:42419.
  • 18
    Engdahl C, Jochems C, Windahl SH et al. Amelioration of collagen-induced arthritis and immune-associated bone loss through signaling via estrogen receptor alpha, and not estrogen receptor beta or G protein-coupled receptor 30. Arthritis Rheum 2010; 62:52433.
  • 19
    Erlandsson MC, Gomori E, Taube M, Carlsten H. Effects of raloxifene, a selective estrogen receptor modulator, on thymus, T cell reactivity, and inflammation in mice. Cell Immunol 2000; 205:1039.
  • 20
    Erlandsson MC, Jonsson CA, Lindberg MK, Ohlsson C, Carlsten H. Raloxifene- and estradiol-mediated effects on uterus, bone and B lymphocytes in mice. J Endocrinol 2002; 175:31927.
  • 21
    Onoe Y, Miyaura C, Ito M, Ohta H, Nozawa S, Suda T. Comparative effects of estrogen and raloxifene on B lymphopoiesis and bone loss induced by sex steroid deficiency in mice. J Bone Miner Res 2000; 15:5419.
  • 22
    Holmdahl R, Jansson L, Larsson E, Rubin K, Klareskog L. Homologous type II collagen induces chronic and progressive arthritis in mice. Arthritis Rheum 1986; 29:10613.
  • 23
    Windahl SH, Vidal O, Andersson G, Gustafsson JA, Ohlsson C. Increased cortical bone mineral content but unchanged trabecular bone mineral density in female ERbeta(–/–) mice. J Clin Invest 1999; 104:895901.
  • 24
    Verdrengh M, Jonsson IM, Holmdahl R, Tarkowski A. Genistein as an anti-inflammatory agent. Inflamm Res 2003; 52:3416.
  • 25
    Bremell T, Abdelnour A, Tarkowski A. Histopathological and serological progression of experimental Staphylococcus aureus arthritis. Infect Immun 1992; 60:297685.
  • 26
    Helle M, Boeije L, Aarden LA. Functional discrimination between interleukin 6 and interleukin 1. Eur J Immunol 1988; 18:153540.
  • 27
    Saxne T, Heinegard D. Cartilage oligomeric matrix protein: a novel marker of cartilage turnover detectable in synovial fluid and blood. Br J Rheumatol 1992; 31:58391.
  • 28
    Mansson B, Carey D, Alini M et al. Cartilage and bone metabolism in rheumatoid arthritis. Differences between rapid and slow progression of disease identified by serum markers of cartilage metabolism. J Clin Invest 1995; 95:10717.
  • 29
    Joosten LA, Lubberts E, Helsen MM et al. Protection against cartilage and bone destruction by systemic interleukin-4 treatment in established murine type II collagen-induced arthritis. Arthritis Res 1999; 1:8191.
  • 30
    Holmdahl R, Jansson L, Andersson M. Female sex hormones suppress development of collagen-induced arthritis in mice. Arthritis Rheum 1986; 29:15019.
  • 31
    Jansson L, Holmdahl R. Oestrogen induced suppression of collagen arthritis. IV: progesterone alone does not affect the course of arthritis but enhances the oestrogen-mediated therapeutic effect. J Reprod Immunol 1989; 15:14150.
  • 32
    Yamasaki D, Enokida M, Okano T, Hagino H, Teshima R. Effects of ovariectomy and estrogen replacement therapy on arthritis and bone mineral density in rats with collagen-induced arthritis. Bone 2001; 28:63440.
  • 33
    Jansson L, Mattsson A, Mattsson R, Holmdahl R. Estrogen induced suppression of collagen arthritis. V: physiological level of estrogen in DBA/1 mice is therapeutic on established arthritis, suppresses anti-type II collagen T-cell dependent immunity and stimulates polyclonal B-cell activity. J Autoimmun 1990; 3:25770.
  • 34
    Nuttall ME, Fisher PW, Suva LJ, Gowen M. The selective oestrogen receptor modulators idoxifene and raloxifene have fundamentally different cell-specific oestrogen-response element (ERE)-dependent/independent mechanisms in vitro. Eur J Cancer 2000; 36 (Suppl. 4):S634.
  • 35
    Yang NN, Venugopalan M, Hardikar S, Glasebrook A. Identification of an estrogen response element activated by metabolites of 17beta-estradiol and raloxifene. Science 1996; 273:12225.
  • 36
    Paech K, Webb P, Kuiper GG et al. Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites. Science 1997; 277:150810.
  • 37
    Weisz A, Rosales R. Identification of an estrogen response element upstream of the human c-fos gene that binds the estrogen receptor and the AP-1 transcription factor. Nucleic Acids Res 1990; 18:5097106.
  • 38
    Blanque R, Cottereaux C, Gardner CR. Increases in osteocalcin after ovariectomy are amplified by LPS injection: strain differences in bone remodelling. Gen Pharmacol 1998; 30:516.
  • 39
    Gao Y, Grassi F, Ryan MR et al. IFN-gamma stimulates osteoclast formation and bone loss in vivo via antigen-driven T cell activation. J Clin Invest 2007; 117:12232.
  • 40
    Amirahmadi SF, Pho MH, Gray RE et al. An arthritogenic monoclonal antibody to type II collagen, CII-C1, impairs cartilage formation by cultured chondrocytes. Immunol Cell Biol 2004; 82:42734.
    Direct Link:
  • 41
    Crombie DE, Turer M, Zuasti BB et al. Destructive effects of murine arthritogenic antibodies to type II collagen on cartilage explants in vitro. Arthritis Res Ther 2005; 7:R92737.
  • 42
    Amirahmadi SF, Whittingham S, Crombie DE et al. Arthritogenic anti-type II collagen antibodies are pathogenic for cartilage-derived chondrocytes independent of inflammatory cells. Arthritis Rheum 2005; 52:1897906.
  • 43
    Nandakumar KS, Bajtner E, Hill L et al. Arthritogenic antibodies specific for a major type II collagen triple-helical epitope bind and destabilize cartilage independent of inflammation. Arthritis Rheum 2008; 58:18496.